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Background: Secondary hyperparathyroidism (SHPT) is associated with mortality in patients with chronic kidney
disease (CKD), but the economic consequences of SHPT have not been adequately studied in the European
population. We assessed the relationship between SHPT parameters (intact parathyroid hormone [iPTH], calcium,
and phosphate) and hospitalisations, medication use, and associated costs among CKD patients in Europe.
Methods: The analysis of this retrospective cohort study used records of randomly selected patients who
underwent haemodialysis between January 1, 2005 and December 31, 2006 at participating European Fresenius
Medical Care facilities in 10 countries. Patients had ≥ 1 iPTH value recorded, and ≥ 1 month of follow-up after a
3-month baseline period during which SHPT parameters were assessed. Time at risk was post-baseline until death,
successful renal transplantation, loss to follow-up, or the end of follow-up. Outcomes included cost per patient-
month, rates of hospitalisations (cardiovascular disease [CVD], fractures, and parathyroidectomy [PTX]), and use of
SHPT-, diabetes-, and CVD-related medications. National costs were applied to hospitalisations and medication use.
Generalised linear models compared costs across strata of iPTH, total calcium, and phosphate, adjusting for baseline
covariates.
Results: There were 6369 patients included in the analysis. Mean ± SD person-time at risk was 13.1 ± 6.4 months.
Patients with iPTH > 600 pg/mL had a higher hospitalisation rate than those with lower iPTH. Hospitalisation rates
varied little across calcium and phosphate levels. SHPT-related medication use varied with iPTH, calcium, and
phosphate. After adjusting for demographic and clinical variables, patients with baseline iPTH > 600 pg/mL had
41% (95% CI: 25%, 59%) higher monthly total healthcare costs compared with those with iPTH in the K/DOQI target
range (150–300 pg/mL). Patients with baseline phosphate and total calcium levels above target ranges (1.13–1.78
mmol/L and 2.10–2.37 mmol/L, respectively) had 38% (95% CI: 27%, 50%) and 8% (95% CI: 0%, 17%) higher
adjusted monthly costs, respectively. Adjusted costs were 25% (95% CI: 18%, 32%) lower among patients with
baseline phosphate levels below the target range. Results were consistent in sensitivity analyses.
Conclusions: These data suggest that elevated SHPT parameters increase the economic burden of CKD in Europe.* Correspondence: schiroli@amgen.com
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A significant proportion of patients with chronic kidney
disease (CKD) progress to end-stage renal disease (ESRD),
corresponding to CKD Stage 5, the National Kidney
Foundation’s Kidney Disease Outcomes Quality Initiative
(K/DOQI) classification for kidney failure [1]. Patients
with ESRD generally require dialysis or transplantation
[1], and those living with the disease experience increased
morbidity, including high rates of hospitalisation for infec-
tion, cardiovascular interventions, and inpatient vascular
access procedures [2].
Secondary hyperparathyroidism (SHPT) is one of the
common sequelae of ESRD that contributes to excess
morbidity and mortality. The key manifestation of SHPT
is an increase in parathyroid hormone (PTH) levels due
to decreased renal function and inhibition of mineral
metabolism [3]. Recent Kidney Disease: Improving Glo-
bal Outcomes (KDIGO) guidelines suggest maintaining
intact plasma PTH (iPTH) levels for dialysed patients in
CKD Stage 5 within approximately two to nine times the
upper normal limit for the assay being used [4]. Prior to
2009, however, dialysis centres followed the K/DOQI
guidelines that advocated a target iPTH range of
150–300 pg/mL for patients in CKD stage 5 [5]. In
Europe an estimated 27% of patients with ESRD have
iPTH higher than the K/DOQI target range [6].
Elevated iPTH levels in dialysis patients are associated
with increased risk of fracture [7,8], extraskeletal calcifi-
cation [9,10], renal osteodystrophy [11], and cardiovas-
cular disease (CVD) [12-14].
SHPT and abnormal calcium and phosphate metabol-
ism pose a growing challenge to healthcare systems,
accounting for a major proportion of the healthcare re-
source utilisation and costs associated with treatment of
ESRD and earlier stages of CKD [15]. Abnormal serum
levels of PTH, phosphate, and calcium were found to be
significantly associated with hospitalisation rates in dia-
lysis patients in the US [16]. In a retrospective analysis,
Schumock et al. [17] examined healthcare utilisation and
costs among diabetic pre-ESRD CKD patients with and
without SHPT, identified on the basis of diagnostic
codes. Utilisation and costs (in 2004 US$) of prescription
drugs, outpatient services, and hospitalisations were all
significantly higher in patients with SHPT than in those
without SHPT, even after multivariate adjustment for
demographic and clinical covariates. Total healthcare
costs were 320% higher in diabetic CKD patients with
SHPT compared with those without SHPT [17]. Khan
et al. [18] estimated the cost contribution of elevated
iPTH levels in CKD patients in the US with congestive
heart failure (CHF), all in stages prior to ESRD at base-
line. Patients with iPTH ≥ 65 pg/mL had US$205 higher
mean monthly CHF-related hospitalisation costs (in
2005 US$) in the period 1 to 3 months preceding dialysiscompared with patients with iPTH < 65 pg/mL (below
the upper bound of the K/DOQI target range for
patients with Stage 3 CKD: 35–70 pg/mL [5]).
Given the differences in clinical practice patterns and
patient populations that exist between Europe and the
US, it is unknown whether a relationship exists between
SHPT markers and healthcare resource use and costs in
European patients. To better understand the economic
burden of SHPT in ESRD patients in Europe, we
assessed the relationship between levels of SHPT para-
meters and SHPT-related hospitalisation, medication
use, and associated costs in a cohort of patients in
both Western and Eastern Europe from the European




The analysis of data from a retrospective cohort study
used records from the European Clinical Database
(EuCliD), a registry of medical data from HD patients at
EU-FME dialysis centres, methodological details of which
have been previously described [19]. Briefly, EuCliD con-
tains detailed patient-level information on medical and
drug history for all HD patients registered with the
EU-FME, including records of key biochemical measure-
ments and medications, and data on patient diagnoses,
hospitalisations, and death codes based on the World
Health Organization’s International Classification of
Diseases, 10th Revision (ICD-10) coding scheme. The
present analysis comprised EuCliD data for randomly
selected patients who underwent HD between January 1,
2005 and December 31, 2006 at participating EU-FME
dialysis facilities in 10 countries: Czech Republic, France,
Hungary, Italy, Poland, Portugal, Slovak Republic,
Slovenia, Spain, and Turkey. Selection criteria and charac-
teristics of this source population have been reported else-
where [20]. Patients attending centres where the majority
of data on key dialysis parameters were missing were
excluded, as were patients from the UK because informa-
tion on medication use was not available for UK centres
[20]. Patient data were anonymised, and informed consent
was obtained from all patients by EU-FME [20].
The cohort study did not include any human or ani-
mal experimentation for which ethical approval was
required. All ethical and regulatory obligations concern-
ing the use of patient data were met at each participating
European Fresenius Medical Care study site. Because
our analysis used existing data, there were no risks
posed to human life. All patient information had been
anonymised by Fresenius Medical Care prior to transfer
of data for analysis. Permission was received from
Fresenius Medical Care to use the database for this ana-
lysis. Fresenius Medical Care data were provided through a
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Patient selection
To be eligible for the present analysis, patients were
required to have at least one iPTH value recorded, and
at least 1 month of follow-up after a 3-month baseline
period during which SHPT parameters (iPTH, total cal-
cium, and phosphate) were assessed. The baseline period
was defined as the 3-month period starting on the date
of the first recorded iPTH measurement. The SHPT
parameters were defined as the mean value of the above
laboratory measures taken during the 3-month baseline
period. Since these parameters fluctuate over time [21],
use of mean values during the 3-month period rather
than at a single assessment helped to minimise potential
exposure misclassification. Time at risk was defined as
the time after the 3-month baseline period until death,
successful renal transplantation, loss to follow-up, or the
end of follow-up (December 31, 2006).
Outcomes
Healthcare resource utilisation outcomes for this study
included SHPT-related hospitalisations and medications.
Hospitalisations potentially related to SHPT were
defined as those associated with CVD, fracture, and
parathyroidectomy (PTX). EuCliD records for the
selected patients were used to calculate both the rate per
100 patient-years and the 12-month cumulative inci-
dence of relevant hospitalisations, identified on the basis
of ICD-10 codes as listed in Additional file 1: Table S1.
CVD-, fracture-, and PTX-related hospitalisations were
assessed separately and also combined as all–SHPT-
related hospitalisations.
SHPT-related medications identified in the database
included phosphate binders, oral vitamin D sterols, and
MimparaW (cinacalcet). Drugs for treating diabetes and
CVD were also assessed separately. Included drugs are
listed in Additional file 2: Table S2. Medication outcomes
were number of days of treatment per patient-year and
percentage of patients prescribed these medications.
Economic outcomes were the cost per month of CVD-,
fracture-, and PTX-related hospitalisations, as well as the
monthly cost of medications associated with treatment of
SHPT, diabetes, and CVD. Diabetes and CVD medica-
tions were included because both comorbidities are asso-
ciated with elevated SHPT parameters [13,22] and with
morbidity and mortality in ESRD patients on HD [16,23].
The cost of each episode of hospitalisation related to
CVD, fracture, or PTX was calculated by mapping the
relevant ICD-10 code to country-specific diagnosis-
related groups (DRGs) and their associated costs. French
DRGs were used for costing for Turkey, where national
DRG costs were not yet available. French DRGs werechosen over other nations’ for this purpose because they
offered the combination of being available online, well
documented, and weighted by different diagnoses. Costs
of each episode of medication use were computed by
mapping the medication and prescribed dose to an asso-
ciated cost using national price lists for each country.
Cost analyses included costs for both SHPT-related and
non–SHPT-related (i.e., diabetes- and CVD-related) drug
use. Hospitalisation and medication price lists were
obtained for 2006 wherever available, with missing prices
retrieved for other years and adjusted for inflation to
2006 Euros using the healthcare component of the Con-
sumer Price Index.
Outcomes were stratified by baseline iPTH, total cal-
cium, and phosphate. Values for each of these SHPT
parameters were divided into clinically relevant categor-
ies, using the K/DOQI target range for each parameter
for CKD Stage 5 as the reference category: 150–300 pg/mL
for iPTH, 2.10–2.37 mmol/L for total calcium, and
1.13–1.78 mmol/L for phosphate [5]. Target ranges from
the 2003 K/DOQI guidelines [5] were used rather than
those from the 2009 KDIGO guidelines [4] because the
former were followed during the study period (2006).
All countries were included in the analyses of health-
care resource utilisation. The cost analyses comprised
patients only from the following five countries with
≥ 1000 patients enrolled in EU-FME/EuCliD: Hungary,
Italy, Portugal, Spain, and Turkey.
Statistical analysis
Hospitalisation rates were calculated by summing the
number of relevant hospitalisation episodes across all
patients and dividing by the person-time at risk for all
patients. The 95% confidence interval was calculated
assuming a Poisson distribution.
One-year cumulative incidence of hospitalisation (all-
cause, as well as related to CVD, fractures, or PTX) was
obtained with the Kaplan–Meier method and 95% confi-
dence intervals using the arcsine-square root transform-
ation. Data for patients not hospitalised were censored
at the last known follow-up date or the end of follow-up
(December 31, 2006).
The number of days of treatment per patient-year with
phosphate binders, oral vitamin D sterols, and cinacalcet
was calculated by summing the number of days when
these medications were received during the time at risk
and dividing by the person-time at risk.
The total cost per month was defined for each patient
as the sum of costs for hospitalisations (CVD-, fracture-,
and PTX-related) and medications (for SHPT, diabetes,
and CVD) divided by the number of months at risk.
Univariate and multivariate analyses exploring the as-
sociation of baseline SHPT parameters with cost per
month were performed using generalised linear models
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link function. To account for patients with zero costs in
the analyses, €1 was added to the total cost per month.
The univariate analysis for each SHPT parameter was
adjusted for the duration of follow-up. The multivariate
analysis included all SHPT parameters and duration of fol-
low-up, and was also adjusted for the following potentially
confounding factors: age, sex, CKD aetiology, history of
CVD, diabetes and cancer, dialysis vintage, C-reactive
protein, albumin, haemoglobin, ferritin, total cholesterol,
and blood leukocyte count.
Results are presented for observed data, with no im-
putation of missing values. All statistical analyses were
performed using SASW (version 9.1, Cary, NC).
Sensitivity analyses
To assess heterogeneity in duration of follow-up times
between patients, a sensitivity analysis was conducted to
compare results for patients with fixed periods of
follow-up, defined as starting after the baseline period.
The multivariate GLM in the main analysis was repeated
for patients with a fixed follow-up time of 3 months,
and again for patients with a fixed follow-up time of 6
months. These two sensitivity analyses included only
patients with at least 3 and 6 months of follow-up,
respectively, and in the analyses their follow-up time
was truncated to these fixed periods.
In addition to the main analysis based on a one-part
model, a two-part multivariate model was fitted in orderFigure 1 Patient geographic distribution.to assess if the choice of the €1 additive factor in the
cost per month affected the results. A two-part model is
a mixture model in which the first part models the prob-
ability of a patient having a cost and the second part
estimates the cost given a patient has a cost. The overall
cost is the product of the first-part estimated probability
and the second-part predicted conditional cost [24].
Lastly, to account for the presence of censored cost
data, the weighted linear regression model proposed by
Lin [25] was fitted. The study period was partitioned
into several time intervals in order to include complete
interval cost information where available. This approach
aims to recreate the pseudo-population that would have
been observed had no censoring occurred.
Results
Patient disposition and characteristics
Of the 6369 patients included from the 10 countries
(see Figure 1), 1496 (23%) discontinued before the
end of the follow-up period: 857 (13%) died, 373 (6%)
were lost to follow-up, and 266 (4%) underwent suc-
cessful renal transplant. Mean ± SD person-time at
risk for the study cohort was 13.1 ± 6.4 months
(range 1–21 months).
The mean ± SD age of the cohort was 63.0 ± 14.7
years, and more than half (57%) were male (see Table 1).
Approximately three quarters of patients had a history
of CVD, and a quarter had a history of diabetes.
Increased iPTH values during the baseline period were
Table 1 Patient characteristics at the beginning of the study by baseline iPTH level, all 10 countries
Baseline iPTH*, pg/mL Total
< 75 ≥ 75 – < 150 ≥ 150 – ≤ 300 > 300 – ≤ 600 > 600 > 800
N patients 1217 1365 1690 1343 754 472 6369
Males, n (%) 641 (53) 809 (59) 1019 (60) 767 (57) 394 (52) 233 (49) 3630 (57)
Age, years 63.6 (14.7) 64.7 (14.1) 64.2 (14.2) 62.0 (14.8) 58.2 (15.7) 57.5 (15.6) 63.0 (14.7)
Dialysis vintage†, months 43.9 (52.7) 37.8 (47.2) 40.9 (53.0) 49.0 (62.2) 66.5 (64.8) 70.6 (64.9) 45.5 (56.0)
History, n (%)
Diabetes 352 (29) 404 (30) 447 (26) 276 (21) 102 (14) 56 (12) 1581 (25)
CVD 978 (80) 1075 (79) 1302 (77) 1020 (76) 589 (78) 368 (78) 4964 (78)
CKD aetiology, n (%)
Hypertension/vascular 167 (14) 189 (14) 249 (15) 189 (14) 92 (12) 64 (14) 886 (14)
Glomerulonephritis 196 (16) 234 (17) 263 (16) 229 (17) 146 (19) 95 (20) 1068 (17)
Diabetes 208 (17) 208 (15) 268 (16) 153 (11) 54 (7) 27 (6) 891 (14)
Tubulo-interstitial 178 (15) 187 (14) 220 (13) 171 (13) 120 (16) 80 (17) 876 (14)
Polycystic kidney disease 60 (5) 73 (5) 100 (6) 83 (6) 67 (9) 43 (9) 383 (6)
Miscellaneous 37 (3) 40 (3) 78 (5) 61 (5) 34 (5) 20 (4) 250 (4)
Unknown 257 (21) 309 (23) 392 (23) 348 (26) 190 (25) 116 (25) 1496 (23)
Missing 114 (9) 125 (9) 120 (7) 109 (8) 51 (7) 27 (6) 519 (8)
CKD, chronic kidney disease; CVD, cardiovascular disease; iPTH, intact parathyroid hormone.
*Mean iPTH during 3-month baseline period.
†Calculated from initiation of dialysis to the start of the 3-month baseline period.
Values are mean (SD) unless specified otherwise.
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lysis vintage, and in lower proportions of male and dia-
betic patients. Patients who completed follow-up had
similar demographics and baseline characteristics to
those who discontinued prior to the end of follow-up,
though a higher percentage of non-completers than
completers had a history of diabetes (30% vs. 23%, re-
spectively) and CVD (83% vs. 76%, respectively) (see
Additional file 3: Table S3). Non-completers also had
higher mean C-reactive protein levels compared with
completers (14.43 vs. 11.77 mg/L, respectively).
Healthcare resource utilisation
Overall, the all–SHPT-related hospitalisation rate was
6.6 (95% CI: 6.0, 7.3) per 100 patient-years. Patients with
baseline iPTH > 600 pg/mL had higher all–SHPT- and
PTX-related hospitalisation rates than those with lower
baseline iPTH (see Figure 2A). However, there was no
obvious trend for CVD- and fracture-related hospitalisa-
tion rates across baseline iPTH levels. All–SHPT-related
hospitalisation rates varied little across baseline total cal-
cium levels (see Figure 2B). Similarly, there was no clear
trend for all–SHPT-related hospitalisation rates to vary
across baseline phosphate levels, although fracture-
related hospitalisations decreased, and PTX-related hos-
pitalisations increased with higher baseline phosphate
(see Figure 2C). Findings were similar for 1-year cumula-
tive incidence of hospitalisation (data not shown).During follow-up 76% of patients received phos-
phate binders, 39% received oral vitamin D sterols,
and 4% received cinacalcet (see Figure 3). The per-
centage of patients using SHPT-related medications
and the number of days of treatment per patient-year
were both higher at elevated baseline iPTH levels for
phosphate binders and cinacalcet, and were highest at
intermediate baseline iPTH levels for oral vitamin D
sterols (see Figure 3A and Figure 4A). The percentage
of patients using medication and the number of days
of treatment per patient-year were higher at elevated
baseline total calcium levels for cinacalcet but not for
phosphate binders or oral vitamin D sterols (see
Figure 3B and Figure 4B). The percentage of patients
using medication and the number of days of treat-
ment per patient-year were higher at elevated baseline
phosphate levels for cinacalcet and phosphate binders
but not for oral vitamin D sterols (see Figure 3C and
Figure 4C).
Healthcare costs
The cost of healthcare resource utilisation (compris-
ing the costs of CVD-, fracture-, and PTX-related
hospitalisations and SHPT-, diabetes-, and CVD-
related medications) increased with rising baseline
iPTH (see Table 2). Mean monthly total healthcare
costs were approximately €37 higher for patients with
baseline iPTH > 600 pg/mL and €41 higher for those
Figure 2 Hospitalisations by baseline SHPT parameters, all 10 countries. CVD, cardiovascular disease; iPTH, intact parathyroid hormone; PTX,
parathyroidectomy; SHPT, secondary hyperparathyroidism. *Mean during 3-month baseline period. †CVD-, fracture- or PTX-related.
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Figure 3 Use of SHPT-related medications by baseline SHPT parameters, all 10 countries. iPTH, intact parathyroid hormone. *Mean during
3-month baseline period.
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Figure 4 Days of treatment with SHPT-related medications by baseline SHPT parameters, all 10 countries. iPTH, intact parathyroid
hormone. *Mean during 3-month baseline period.
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Table 2 Total healthcare cost per month by baseline iPTH, Hungary, Italy, Portugal, Spain, and Turkey
Baseline iPTH*, pg/mL Total
< 75 ≥ 75 – < 150 ≥ 150 – ≤ 300 > 300 – ≤ 600 > 600 > 800
N patients 1054 1145 1394 1140 653 405 5386
Total cost per month (including patients with zero costs), 2006 €
Mean 60.52 67.01 73.47 82.46 109.97 114.12 75.89
SD 196.55 300.32 264.06 156.54 168.81 192.30 231.52
Median 16.15 22.34 26.66 41.68 57.69 56.57 28.61
Q1, Q3 5.01, 52.09 7.85, 69.08 9.18, 79.33 12.05, 101.16 14.88, 131.21 13.37, 132.83 8.55, 83.69
Min, Max 0.00, 3895.54 0.00, 9533.54 0.00, 7518.35 0.00, 3790.69 0.00, 2031.16 0.00, 2031.16 0.00, 9533.54
Patients with total
cost per month
> €0, n (%)
937 (89) 1052 (92) 1284 (92) 1060 (93) 605 (93) 372 (92) 4938 (92)
Cost of hospitalisations per month (including patients with zero costs), 2006 €
Mean 23.40 23.21 21.50 17.87 25.51 29.49 21.95
SD 188.45 295.38 254.07 137.19 129.88 152.03 219.56
Median 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Q1, Q3 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00




> €0, n (%)
40 (4) 50 (4) 51 (4) 63 (6) 50 (8) 34 (8) 254 (5)
Cost of medications per month (including patients with zero costs), 2006 €
Mean 37.12 43.81 51.97 64.59 84.46 84.63 53.94
SD 54.32 56.55 70.41 76.68 103.14 107.58 72.70
Median 14.98 21.01 24.88 39.44 52.30 49.35 26.02
Q1, Q3 4.71, 48.12 7.34, 60.07 8.74, 71.46 11.20, 92.55 13.01, 112.43 11.38, 111.02 8.04, 74.56
Min, Max 0.00, 445.09 0.00, 418.67 0.00, 709.97 0.00, 698.08 0.00, 676.07 0.00, 676.07 0.00, 709.97
Patients with
medication cost per
month > €0, n (%)
933 (89) 1049 (92) 1281 (92) 1054 (92) 603 (92) 372 (92) 4920 (91)
iPTH, intact parathyroid hormone.
*Mean iPTH during 3-month baseline period.
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patients whose iPTH levels were within the K/DOQI
target range at baseline (mean [interquartile range]
€109.97 [14.88, 131.21], €114.12 [13.37, 132.83], and
€73.47 [9.18, 79.33], respectively). Mean monthly
medication costs increased with higher baseline iPTH,
whereas there was no clear relationship between
mean monthly hospitalisation costs and iPTH.
Patients with baseline total calcium above the K/DOQI
target range of 2.10–2.37 mmol/L had approximately
€14 higher mean monthly costs than patients with
baseline total calcium levels within the target range
(mean [interquartile range] €86.09 [9.88, 104.82] vs.
€72.57 [8.32, 79.72], respectively) (see Table 3). Mean
monthly medication costs increased with higher base-
line total calcium, but mean monthly hospitalisationcosts did not show a clear trend in relation to total
calcium.
Mean (interquartile range) monthly total healthcare
costs increased with increasing baseline phosphate
levels, from €62.02 (4.48, 54.32) among patients with
phosphate < 1.13 mmol/L, to €75.27 (8.51, 82.41)
among those in the K/DOQI target range of 1.13–
1.78 mmol/L, and €88.88 (14.49, 107.77) among
those with phosphate > 1.78 mmol/L (see Table 4).
Mean monthly medication costs increased with
higher baseline phosphate, while mean monthly hos-
pitalisation costs were not clearly associated with
phosphate levels.
Additional file 4: Table S4, Additional file 5: Table S5,
and Additional file 6: Table S6 present cost results for
the component hospitalisation and medication categories
Table 3 Total healthcare cost per month by baseline total calcium, Hungary, Italy, Portugal, Spain, and Turkey
Baseline total calcium*, mmol/mL Total
< 2.10 ≥ 2.10 – ≤ 2.37 > 2.37 Missing
N patients 833 2980 1405 168 5386
Total cost per month (including patients with zero costs), 2006 €
Mean 70.52 72.57 86.09 75.96 75.89
SD 308.29 233.85 171.97 171.79 231.52
Median 23.02 25.83 37.39 36.51 28.61
Q1, Q3 7.34, 68.65 8.32, 79.72 9.88, 104.82 9.87, 78.81 8.55, 83.69
Min, Max 0.00, 7518.35 0.00, 9533.54 0.00, 3790.69 0.00, 1766.00 0.00, 9533.54
Patients with total cost per month > €0, n (%) 759 (91) 2742 (92) 1274 (91) 163 (97) 4938 (92)
Cost of hospitalisations per month (including patients with zero costs), 2006 €
Mean 26.33 21.08 19.91 32.71 21.95
SD 303.23 221.58 150.74 171.24 219.56
Median 0.00 0.00 0.00 0.00 0.00
Q1, Q3 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00
Min, Max 0.00, 7501.80 0.00, 9533.54 0.00, 3790.69 0.00, 1766.00 0.00, 9533.54
Patients with hospitalisation cost per month > €0, n (%) 33 (4) 136 (5) 74 (5) 11 (7) 254 (5)
Cost of medications per month (including patients with zero costs), 2006 €
Mean 44.19 51.49 66.18 43.25 53.94
SD 61.73 70.83 83.31 40.75 72.70
Median 20.08 23.49 35.89 32.38 26.02
Q1, Q3 6.32, 59.11 7.89, 70.28 9.26, 91.74 8.51, 64.91 8.04, 74.56
Min, Max 0.00, 549.78 0.00, 709.97 0.00, 589.91 0.00, 159.19 0.00, 709.97
Patients with medication cost per month > €0, n (%) 754 (91) 2737 (92) 1269 (90) 160 (95) 4920 (91)
*Mean total calcium during 3-month baseline period.
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levels, respectively.
The observed increase in costs with increasing
iPTH persisted after adjustment for follow-up dur-
ation in the univariate analysis, and also after adjust-
ment for follow-up duration and several demographic
and clinical variables in the multivariate analysis (see
Table 5). On average, patients with baseline iPTH >
600 pg/mL had 41% (95% CI: 25%, 59%) higher
healthcare costs per month compared to patients with
baseline iPTH levels in the K/DOQI target range, all
else being equal. While the relative cost of healthcare
resource utilisation increased with baseline total cal-
cium above the reference range (i.e., > 2.37 mmol/L),
the magnitude of this cost increase was small: 8%
(95% CI: 0%, 17%) in the multivariate analysis (see
Table 5). Relative costs were similar among patients
with baseline total calcium below and within the
reference range. In contrast, there was a 38% (95%
CI: 27%, 50%) increase and a 25% (95% CI: 18%, 32%)
decrease in relative cost of healthcare resource utilisa-
tion for patients with baseline phosphate above andbelow the reference range, respectively (i.e., > 1.78
mmol/L and < 1.13 mmol/L) (see Table 5).
Associations between baseline iPTH level and relative
healthcare costs for each of the five countries in the
relative-cost analysis generally followed the trend for the
five countries combined, although the trend appeared to
be stronger in Spain and weaker in Portugal (see
Figure 5). This may reflect different costs for hospitalisa-
tions and medications between countries. Portugal had
more patients with missing values of baseline total
calcium and phosphate compared to other countries for
reasons we could not identify.Sensitivity analyses
In sensitivity analyses, the multivariate model was
repeated for patients with fixed duration of follow-up
time. Results trended in the same direction for patients
with fixed follow-up times of 3 or 6 months (see Table 6).
Relative costs in the two-part sensitivity analysis were
consistent with relative costs in the main analysis, sug-
gesting that addition of €1 to all monthly costs in the
Table 4 Total healthcare cost per month by baseline phosphate, Hungary, Italy, Portugal, Spain, and Turkey
Baseline phosphate*, mmol/mL Total
< 1.13 ≥ 1.13 – ≤ 1.78 > 1.78 Missing
N patients 827 3104 1208 247 5386
Total cost per month (including patients with zero costs), 2006 €
Mean 62.02 75.27 88.88 66.60 75.89
SD 176.01 273.40 145.08 147.07 231.52
Median 15.24 26.66 46.00 28.57 28.61
Q1, Q3 4.48, 54.32 8.51, 82.41 14.49, 107.77 10.65, 72.60 8.55, 83.69
Min, Max 0.00, 3790.69 0.00, 9533.54 0.00, 2031.16 0.00, 1766.00 0.00, 9533.54
Patients with cost per month > €0, n (%) 732 (89) 2856 (92) 1116 (92) 234 (95) 4938 (92)
Cost of hospitalisations per month (including patients with zero costs), 2006 €
Mean 24.81 22.53 17.87 25.05 21.95
SD 165.02 264.57 111.07 142.43 219.56
Median 0.00 0.00 0.00 0.00 0.00
Q1, Q3 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00 0.00, 0.00
Min, Max 0.00, 3790.69 0.00, 9533.54 0.00, 1879.98 0.00, 1766.00 0.00, 9533.54
Patients with hospitalisation cost per month > €0, n (%) 50 (6) 130 (4) 60 (5) 14 (6) 254 (5)
Cost of medications per month (including patients with zero costs), 2006 €
Mean 37.21 52.74 71.01 41.55 53.94
SD 60.95 69.83 87.04 44.81 72.70
Median 13.45 24.96 41.28 27.11 26.02
Q1, Q3 3.89, 45.32 8.12, 74.40 13.37, 95.17 10.57, 62.62 8.04, 74.56
Min, Max 0.00, 549.78 0.00, 709.97 0.00, 676.07 0.00, 365.41 0.00, 709.97
Patients with medication cost per month > €0, n (%) 727 (88) 2848 (92) 1112 (92) 233 (94) 4920 (91)
*Mean phosphate during 3-month baseline period.
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Table 6).
A similar trend was observed in the sensitivity ana-
lysis using the Lin method [25] for all countries com-
bined, with higher monthly mean costs occurring in
patients with elevated baseline iPTH levels. For
patients with baseline iPTH < 75, ≥ 75 – < 150,
≥ 150 – ≤ 300, > 300 – ≤ 600, and > 600 pg/mL, mean
monthly costs (95% CI) were estimated to be €52.68
(50.30, 55.34), €56.30 (53.78, 58.50), €62.96 (60.74,
65.07), €83.86 (81.45, 86.11), and €111.53 (108.54,
114.64), respectively. Trends were also consistent for
each of the individual countries except Turkey. In
Turkey the trend was reversed, with lower monthly
mean costs occurring with increasing baseline iPTH
levels. This could reflect the fact that in Turkey
patients with elevated baseline iPTH levels and high
costs were observed at the start of the follow-up
period where the censoring rate was lower. Conse-
quently, the probabilities of not being censored as-
signed to these costs were higher than for the costs
observed in the other iPTH levels, resulting in a dif-
ferent trend than observed in the main analysis.Nevertheless, the two methods aim to address diffe-
rent aspects of the cost data.
Discussion
The major finding of this study in patients in
Western and Eastern Europe on HD is that direct
medical costs were associated with high levels of
iPTH and phosphate above the K/DOQI recom-
mended range for patients with ESRD. Healthcare
costs were higher with elevated phosphate and (to a
lesser degree) total calcium even after adjustment for
iPTH level and numerous other potentially confounding
variables. Furthermore, medical costs were lower among
patients with baseline phosphate levels below the K/DOQI
target range.
This study assessed SHPT parameters in relation to
the target ranges for patients in CKD Stage 5 recom-
mended in the K/DOQI guidelines [5] rather than
those from the more recent KDIGO guidelines [4]
that were developed after the study period. The
KDIGO guidelines did not prescribe numeric target
ranges for these parameters, instead suggesting main-
taining iPTH, total calcium, and phosphate in relation
Table 5 Relative healthcare cost per month by baseline
SHPT parameters, Hungary, Italy, Portugal, Spain, and
Turkey






< 75 1054 1.01 (0.92, 1.12) 0.98 (0.89, 1.09)
≥ 75 – < 150 1145 0.98 (0.89, 1.08) 1.00 (0.91, 1.10)
≥ 150 – ≤ 300 (reference) 1394 1.00 1.00
> 300 – ≤ 600 1140 1.11 (1.01, 1.22) 1.11 (1.01, 1.22)
> 600 653 1.53 (1.36, 1.71) 1.41 (1.25, 1.59)
Total calcium (mmol/L)
< 2.10 mmol/L 833 1.06 (0.97, 1.17) 1.01 (0.92, 1.11)
≥ 2.10 – ≤ 2.37
mmol/L (reference)
2980 1.00 1.00
> 2.37 mmol/L 1405 1.14 (1.06, 1.24) 1.08 (1.00, 1.17)
Missing 168 1.26 (1.03, 1.54) 1.54 (1.18, 2.00)
Phosphate (mmol/L)
< 1.13 mmol/L 827 0.75 (0.68, 0.82) 0.75 (0.68, 0.82)
≥ 1.13 – ≤ 1.78
mmol/L (reference)
3104 1.00 1.00
> 1.78 mmol/L 1208 1.39 (1.28, 1.51) 1.38 (1.27, 1.50)
Missing 247 0.94 (0.79, 1.12) 0.70 (0.55, 0.88)
iPTH, intact parathyroid hormone.
*Mean during 3-month baseline period.
†Adjusted for duration of follow-up.
‡Adjusted for iPTH, total calcium, phosphate, duration of follow-up, age, sex,
chronic kidney disease aetiology, history of cardiovascular disease, diabetes
and cancer, dialysis vintage, C-reactive protein, albumin, haemoglobin, ferritin,
total cholesterol and blood leukocyte count.
Figure 5 Relative healthcare cost per month by baseline iPTH level. *
phosphate, duration of follow-up, and baseline factors. Error bars are 95% c
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http://www.biomedcentral.com/1471-2369/13/140to assay reference ranges [26]. For iPTH, the range
suggested in the KDIGO guidelines for CKD Stage 5
patients on dialysis corresponds to approximately
130–600 pg/mL, taking into account the different
iPTH assays in use commercially [26], and therefore
our findings of increased costs in patients with iPTH
> 600 pg/mL would be expected to apply in relation
to the KDIGO target range.
As noted above, studies in CKD patients in the US
by Schumock et al. [17] and Khan et al. [18] have
previously shown that SHPT can substantially increase
healthcare costs. Results of these US studies are not
directly comparable to ours due to patients’ different
CKD stages at baseline and the focus on patients with
diabetes by Schumock et al. [17] and on those with
CVD by Khan et al. [18]. Nevertheless, as in the
present analysis, these US studies found that elevated
iPTH is associated with higher healthcare costs for
CKD patients. Conversely, Smith et al. [27] found no
significant association between iPTH level and health-
care costs. This contradictory finding may be due to
Smith et al. [27] assigning zero cost after death, since
patients who died were still included in 1-year cost
calculations and mortality rate was significantly ele-
vated in patients with higher baseline iPTH. Consid-
erable uncertainty in the cost estimates of Smith
et al. [27] should also be noted, potentially attribut-
able to the inclusion of patients in a range of differ-
ent CKD stages, primarily pre-ESRD. In contrast, the
EU-FME source population we investigated had more
severe disease and may represent a more clinically
homogeneous group, which could help to reduce
factors obscuring an influence of iPTH level on costs.iPTH, intact parathyroid hormone. *Adjusted for total calcium,
onfidence intervals.
Table 6 Relative healthcare cost per month by baseline iPTH, total calcium, and phosphate in sensitivity analyses




Total healthcare cost >
€0 (N=4938)
n Relative Cost† (95% CI) n Relative Cost† (95% CI) n Relative Cost†‡ (95% CI)
iPTH, pg/mL
< 75 965 0.90 (0.81, 1.00) 837 0.81 (0.72, 0.90) 937 1.00 (0.91, 1.10)
≥ 75 – < 150 1064 1.02 (0.92, 1.13) 928 1.00 (0.90, 1.11) 1052 0.99 (0.91, 1.09)
≥ 150 – ≤ 300 (reference) 1295 1.00 1124 1.00 1284 1.00
> 300 – ≤ 600 1068 1.14 (1.03, 1.27) 926 1.05 (0.95, 1.17) 1060 1.10 (1.00, 1.20)
> 600 617 1.50 (1.32, 1.70) 555 1.37 (1.20, 1.56) 605 1.40 (1.25, 1.57)
Total calcium (mmol/L)
< 2.10 mmol/L 766 0.96 (0.87, 1.07) 631 0.95 (0.85, 1.06) 759 1.01 (0.92, 1.11)
≥ 2.10 – ≤ 2.37 mmol/L (reference) 2773 1.00 2397 1.00 2742 1.00
> 2.37 mmol/L 1311 1.03 (0.94, 1.12) 1195 1.00 (0.92, 1.10) 1274 1.10 (1.02, 1.19)
Missing 159 1.41 (1.02, 1.96) 147 1.14 (0.82, 1.58) 163 1.52 (1.18, 1.95)
Phosphate (mmol/L)
< 1.13 mmol/L 764 0.77 (0.70, 0.86) 673 0.80 (0.71, 0.89) 732 0.78 (0.71, 0.85)
≥ 1.13 – ≤ 1.78 mmol/L (reference) 2889 1.00 2526 1.00 2856 1.00
> 1.78 mmol/L 1131 1.37 (1.25, 1.50) 960 1.44 (1.31, 1.58) 1116 1.38 (1.27, 1.50)
Missing 225 0.87 (0.64, 1.16) 211 0.85 (0.63, 1.15) 234 0.73 (0.59, 0.92)
iPTH, intact parathyroid hormone.
*Mean during 3-month baseline period.
†Based on pooled data for Hungary, Italy, Portugal, Spain, and Turkey, adjusted for iPTH, total calcium, phosphate, duration of follow-up, age, sex, chronic kidney
disease aetiology, history of cardiovascular disease, diabetes and cancer, dialysis vintage, C-reactive protein, albumin, haemoglobin, ferritin, total cholesterol and
blood leukocyte count.
‡Only the second-part results of the two-part model are presented.
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ment on rates of CVD-, fracture-, and PTX-related
hospitalisation was outside the scope of the present
study. This topic was previously addressed in a
pooled analysis of data from 1184 subjects participat-
ing in four randomised, double-blind clinical trials of
the calcimimetic SHPT medication cinacalcet, which
showed a 54% reduction in the risk of fracture, a 39%
reduction in the risk of CVD-related hospitalisation,
and a 93% reduction in the risk of PTX for patients
receiving cinacalcet compared with those receiving
placebo [28].
The present study has several strengths, including
use of a large, comprehensive, and validated medical
database [19], which has been used in other analyses
of outcomes among patients with ESRD [20,22,29].
Nevertheless, this study has a number of limitations.
Generalisability of our results may be limited because
the patient population represents a select group
undergoing treatment at private HD facilities from a
single network of providers (i.e., EU-FME). Analyses
were restricted by the information available in the
database; for example, costs of vitamin D use may be
underestimated due to no data being collected on
intravenous vitamin D use. A lower-than-expected
rate of hospitalisation was observed, which could bedue to missing registration in the database. The low
number of hospitalisations could also be due to the
relatively short person-time at risk: a mean of 13
months. A longer observational period would prob-
ably have shown more events. Finally, as with any ob-
servational study, the associations reported here are
correlative only. For example, the observed associ-
ation between increased medical cost and levels of
iPTH and phosphate outside the K/DOQI target
ranges could be driven by the effects of more
advanced disease on both costs and levels of SHPT
parameters, rather than by a direct effect of iPTH
and phosphate levels on medical costs.Conclusions
This analysis indicates that elevated levels of iPTH,
phosphate, and (to a lesser extent) total calcium in
patients with ESRD are associated with a greater inten-
sity of healthcare resource utilisation and higher direct
medical costs in comparison with patients whose levels
are within the K/DOQI target ranges. These European
results support the potential association between SHPT
parameters and the economic burden of SHPT in
patients with CKD, as reported for patients in the US
[15,18].
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